Daré Bioscience, Inc. (DARE)
0.80
0.00 (0.00%)
USD |
NASDAQ |
Aug 25, 12:16
Daré Bioscience EPS Diluted (Quarterly) : -0.2003 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2003 |
| March 31, 2026 | -0.2066 |
| December 31, 2025 | -0.0994 |
| September 30, 2025 | -0.2793 |
| June 30, 2025 | -0.4528 |
| March 31, 2025 | -0.4999 |
| September 30, 2024 | -0.551 |
| June 30, 2024 | 1.523 |
| March 31, 2024 | -0.8065 |
| December 31, 2023 | -0.6071 |
| September 30, 2023 | -1.094 |
| June 30, 2023 | -1.217 |
| March 31, 2023 | -1.129 |
| December 31, 2022 | -2.255 |
| September 30, 2022 | -0.9931 |
| June 30, 2022 | 0.0582 |
| March 31, 2022 | -1.201 |
| December 31, 2021 | -1.364 |
| September 30, 2021 | -2.148 |
| June 30, 2021 | -2.18 |
| March 31, 2021 | -1.975 |
| December 31, 2020 | -2.618 |
| September 30, 2020 | -2.883 |
| June 30, 2020 | -3.201 |
| March 31, 2020 | -2.156 |
| Date | Value |
|---|---|
| December 31, 2019 | -2.498 |
| September 30, 2019 | -2.441 |
| June 30, 2019 | -3.533 |
| March 31, 2019 | -3.206 |
| December 31, 2018 | -3.064 |
| September 30, 2018 | -2.705 |
| June 30, 2018 | -3.763 |
| March 31, 2018 | -10.56 |
| December 31, 2017 | -18.12 |
| September 30, 2017 | -3.96 |
| June 30, 2017 | -66.00 |
| March 31, 2017 | -32.40 |
| December 31, 2016 | -20.40 |
| September 30, 2016 | -43.20 |
| June 30, 2016 | -48.00 |
| March 31, 2016 | -58.80 |
| December 31, 2015 | -46.80 |
| September 30, 2015 | -46.80 |
| June 30, 2015 | -44.40 |
| March 31, 2015 | -49.20 |
| December 31, 2014 | -44.40 |
| September 30, 2014 | -33.60 |
| June 30, 2014 | -52.80 |
| March 31, 2014 | -444.00 |
| December 31, 2013 | -3.60 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Nektar Therapeutics | -1.229 |
| Elite Pharmaceuticals, Inc. | 0.0052 |
| Eton Pharmaceuticals, Inc. | 0.3531 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.983M |
| Revenue (Quarterly) | 0.1875M |
| Total Expenses (Quarterly) | 3.170M |
| Enterprise Value | 6.305M |
| Gross Profit Margin (Quarterly) | -294.5% |
| Profit Margin (Quarterly) | -1.59K% |
| Earnings Yield | -98.20% |
| Normalized Earnings Yield | -98.20 |